Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
Exome sequences from thousands of Chinese individuals with or without esophageal squamous cell carcinoma led to six new germline risk variants.
In an initial project, the research team is sequencing esophageal tumor genomes of patients in Tanzania, where it is one of the most common cancers.
Higher levels of oral bacteria like Tannerella forsythia and Porphyromonas gingivalis increased the risk of esophageal cancer, though other bacteria had protective effects.
The team found that cancer-causing genes depend on the BTK gene, which they believe they can shut down with an existing drug.
A new analysis hints that adenocarcinomas or squamous cell carcinomas may have certain overlapping expression patterns, regardless of the tissue of origin.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
In Genome Research this week: esophageal adenocarcinoma sequencing study, the automated BLAST pipeline Leapfrog, and more.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.